Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Balugrastim biosimilar - Jiangsu T-mab BioPharma

Next Previous
Drug Profile

Balugrastim biosimilar - Jiangsu T-mab BioPharma

Alternative Names: GW-003

Latest Information Update: 28 Oct 2018

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu T-mab BioPharma
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Recombinant fusion proteins
  • Mechanism of Action Granulocyte colony stimulating factor replacements; Granulocyte colony-stimulating factor receptor agonists; Granulocyte stimulants; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Neutropenia

Most Recent Events

  • 28 Oct 2018 No recent reports of development identified for phase-I development in Neutropenia(In volunteers, Chemotherapy-induced) in China (SC, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Neutropenia(Chemotherapy-induced) in China (SC, Injection)
  • 01 Mar 2016 Jiangsu T-Mab Biopharma initiates enrolment in a phase I trial in Neutropenia (Chemotherapy-induced) in China (SC) (NCT02725606)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top